Alphamab Oncology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Alphamab Oncology has been growing earnings at an average annual rate of 23.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 56.6% per year.
Belangrijke informatie
23.2%
Groei van de winst
34.2%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | 56.6% |
| Rendement op eigen vermogen | -13.2% |
| Nettomarge | -84.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Alphamab Oncology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 256 | -216 | 81 | 407 |
| 31 Mar 24 | 237 | -213 | 80 | 407 |
| 31 Dec 23 | 219 | -211 | 80 | 407 |
| 30 Sep 23 | 234 | -214 | 78 | 427 |
| 30 Jun 23 | 250 | -218 | 76 | 446 |
| 31 Mar 23 | 208 | -272 | 82 | 457 |
| 31 Dec 22 | 167 | -326 | 87 | 468 |
| 30 Sep 22 | 183 | -309 | 85 | 467 |
| 30 Jun 22 | 200 | -292 | 83 | 466 |
| 31 Mar 22 | 173 | -352 | 80 | 473 |
| 31 Dec 21 | 146 | -412 | 78 | 481 |
| 30 Sep 21 | 73 | -502 | 77 | 455 |
| 30 Jun 21 | 0 | -592 | 76 | 429 |
| 31 Mar 21 | 0 | -510 | 77 | 380 |
| 31 Dec 20 | 0 | -428 | 78 | 331 |
| 30 Sep 20 | 1 | -652 | 106 | 288 |
| 30 Jun 20 | 2 | -877 | 134 | 245 |
| 31 Mar 20 | -1 | -851 | 132 | 208 |
| 31 Dec 19 | 5 | -833 | 118 | 167 |
| 30 Sep 19 | 3 | -495 | 80 | 131 |
| 30 Jun 19 | 1 | -157 | 41 | 95 |
| 31 Mar 19 | 6 | -176 | 29 | 80 |
| 31 Dec 18 | -1 | -150 | 26 | 66 |
| 31 Dec 17 | 1 | -33 | 13 | 53 |
Kwaliteitswinsten: 9966 is currently unprofitable.
Groeiende winstmarge: 9966 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 9966 is unprofitable, but has reduced losses over the past 5 years at a rate of 23.2% per year.
Versnelling van de groei: Unable to compare 9966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 9966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rendement op eigen vermogen
Hoge ROE: 9966 has a negative Return on Equity (-13.24%), as it is currently unprofitable.